Targeting Rs 100 Cr sales in FY 2021-22
Ahmedabad-based Uniza Group has entered into an exclusive tie-up with Lysulin – an innovator company from the US to launch Lysulin – a breakthrough evidence-based nutritional product for Indian Market.
Lysulin is patented in the US for the prevention of protein glycation using Lysine supplements and as a method of diabetes support using a supplement.
Lysulin helps manage blood sugar by binding naturally to the glucose in the blood and safely removing it from the body. When taken daily, Lysulin has been clinically shown to help people with type 2 diabetes and prediabetes maintain healthy blood sugar and A1c levels.
Uniza is a pharmaceutical venture of Pashupati Group. The company has set up a modern, state-of-the-art facility complying with WHO-GMP and PIC/S guidelines at Kadi near Ahmedabad, Gujarat.
Having launched India business in August 2020, the company has gradually expanded its product range to over 80 SKU’s with a sale of Rs 25 crore in the first year.
“Our international business would mainly focus on ROW markets like Africa, LATAM, South East Asia and CIS countries and planning to file over 180 dossiers. Our Indian business is aiming to achieve sales of Rs 100 crore in FY 2021-22,” said Saurin Parikh, MD, Uniza Group & Founder, Pashupati Group.